BIO-TECHNE Corp
Bio-Techne Corp develops, manufactures, and sells life science reagents, instruments, and services used in research, diagnostics, and bioprocessing. Its products support scientific work across protein analysis, molecular diagnostics, cell and gene therapy, and spatial biology. The company operates through two segments: Protein Sciences and Diagnostics and Spatial Biology. A meaningful part of the business is tied to recurring consumables demand from research labs, while another part serves regulated clinical and diagnostic workflows.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueBiological reagents used in life science research, diagnostics, and cell and gene therapy workflows.
Proteomic tools and automated platforms used for protein analysis, western blotting, and multiplexed ELISA.
Controls, calibrators, and diagnostic assays sold into regulated diagnostics markets.
Instrumentation and tissue-based assays for spatial genomic analysis and biopsy workflows.
Products
Reported · share of revenue- Consumables81.1 %
- Instruments9.1 %
- Services7.8 %
- Royalty2.1 %
Source: 10-K FY2026, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Bio-Techne sells primarily to research institutions, pharmaceutical and biotechnology companies, and clinical diagnostics customers. Academic and government labs buy reagents and analytical tools to study biological pathways and disease mechanisms, while pharma and biotech customers use them in drug discovery, assay development, and cell and gene therapy workflows. Diagnostics customers include regulated laboratories and healthcare-related users that need controls, calibrators, assays, and spatial biology tools for clinical or translational applications. The company also serves customers that purchase through distributors and global sales channels, which matters because purchasing decisions are influenced by budget cycles, research funding, and regulatory requirements.
Buys reagents and analytical tools for biological research, with demand tied to grant funding, lab activity, and academic calendars.
Buys protein science reagents, analytical platforms, and assay tools for drug discovery, development, and cell and gene therapy.
Buys diagnostic controls, calibrators, assays, and exosome-based tests for regulated clinical workflows.
Buys tissue-based in-situ hybridization assays and spatial genomic instrumentation for research and clinical applications.
Strategy
Bio-Techne is focused on expanding its global sales force and distribution channels to make it easier for customers to buy and to deepen market reach. The company continues to invest in research and development, introducing more than 400 new products in fiscal 2025, which supports its position in fast-moving research and diagnostics niches. Acquisitions are part of the growth model, with Lunaphore added in fiscal 2024 and a planned full acquisition of Wilson Wolf by 2027, indicating a strategy of filling product and technology gaps. Management also emphasizes customer experience and culture, which supports retention in a market where product quality, service, and application expertise are key differentiators.
Broader sales and distribution coverage helps capture demand across research and diagnostics markets and reduces dependence on any single channel.
Frequent new product introductions are essential in reagent and diagnostics markets where customers expect technical differentiation and workflow improvements.
Complementary acquisitions can add technology, customer relationships, and market access faster than internal development alone.
Geography
Q1/2026Bio-Techne sells worldwide, with a broad international customer base across research and diagnostics markets. The company specifically notes cash balances and operations in the U.S., Canada, China, the U.K., and other European countries, showing a geographically diversified footprint. Its business is exposed to foreign currency movements, local regulatory regimes, and differences in research funding and healthcare spending across regions. Manufacturing and warehouse operations are important to service global demand, and the company also highlighted significant operations in California, which adds operational concentration risk.
Share of the revenue the company reports by geography.
Risks
Bio-Techne faces intense competition from both large global life science companies and smaller niche players, which can pressure pricing, margins, and market share. Demand is exposed to macro conditions, including research funding cycles, healthcare budgets, inflation, currency volatility, and supply chain disruptions, all of which can affect customer purchasing and the company’s own cost base. The business also depends on manufacturing, quality control, packaging, and distribution operations, so any disruption can damage customer relationships and reduce sales. Regulatory and compliance risk is material in diagnostics and laboratory services, especially for products and services tied to FDA rules, privacy laws, billing practices, and physician/hospital relationships.
- Intense competition and pricing pressureImpact: HighLikelihood: Medium
The company competes against large multinationals and niche specialists, and consolidation among customers can concentrate buying power.
Exposure - Operational disruption and quality failureImpact: HighLikelihood: Medium
The business relies on manufacturing, packaging, warehousing, and distribution; any disruption can impair sales and customer trust.
Exposure - Regulatory and privacy complianceImpact: HighLikelihood: Medium
Diagnostics and laboratory services are subject to healthcare, billing, and privacy rules that can trigger penalties or restrictions if breached.
Exposure: Exosome Diagnostics and other regulated diagnostic offerings
- Macro and funding sensitivityImpact: MediumLikelihood: Medium
Customer demand depends on research budgets, healthcare spending, and broader economic conditions.
Exposure
Accounting
Judgemental itemsAcquisitions are central to strategy, and fair value estimates for earn-outs can materially affect liabilities and earnings.
Impact: Can change goodwill, acquisition-related amortization, and reported earnings
The company carries acquired intangibles and goodwill that require periodic impairment testing.
Impact: Potential non-cash write-downs if acquired businesses underperform
Academic calendars and diagnostic test timing create uneven revenue patterns across quarters.
Impact: Quarterly comparability and organic growth trends can be noisy
A disposal group in Diagnostics and Spatial Biology was classified as held-for-sale, affecting presentation and comparability.
Impact: Can alter segment revenue and asset/liability classification
Similar listed companies
Publicly listed companies with a comparable business focus.
Bio-Rad Laboratories, Inc
BIO · Laboratory Analytical Instruments
Bio-Rad Laboratories is a U.S.-based multinational that develops, manufactures, and sells tools used in life science research and clinical diagnostics.
Adaptive Biotechnologies Corp
ADPT · Biological Products, (No Diagnostic Substances)
Adaptive Biotechnologies Corp is a Seattle-based life sciences company built around immune-system sequencing and computational biology.
Bionano Genomics, Inc.
BNGO · Laboratory Analytical Instruments
BioVie Inc
BIVIW · Pharmaceutical Preparations
BioLife Solutions, Inc
BLFS · Electromedical & Electrotherapeutic Apparatus
Repligen Corporation
RGEN · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026